Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 8/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 5/20 | 0.35 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3790975 | 0.89 | SLC6A2 (0.47) | ESR2KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3792713 | 0.86 | SLC6A2 (0.51) | KCNH2SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL3783984 | 0.86 | SLC6A2 (0.42) | KCNH2SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL3787199 | 0.84 | SLC6A2 (0.50) | KCNH2SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL22817120 | 0.80 | ESR2 (0.53) | ESR2KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22817118 | 0.80 | ESR2 (0.53) | ESR2KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22817121 | 0.80 | ESR2 (0.53) | ESR2KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3784884 | 0.74 | SLC6A2 (0.47) | ESR2KCNH2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2407 | 0.74 | SLC6A2 (0.65) | KCNH2SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL7153005 | 0.74 | ESR2 (0.55) | ESR2KCNH2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | ESR2 4547/4885KCNH2 3420/4885SLC6A2 1708/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | ESR2 4547/4885KCNH2 3420/4885SLC6A2 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.